--- title: "AntiFold: Superior Structure-Based Antibody Sequence Design for Enhanced CDR Recovery" description: AI and ML are revolutionizing antibody development. AntiFold, an antibody-specific model using the ESM-IF1 framework, optimizes sequences to enhance properties. image: https://info.genophore.com/hubfs/Thumbnail%20Themes%20(14).svg --- [Skip to content](https://info.genophore.com/posts/antifold-superior-structure-based-antibody-sequence-design-for-enhanced-cdr-recovery#main-content) [![Genophore](https://info.genophore.com/hubfs/Imported%20sitepage%20images/203149784d2ad8223028.svg "Genophore")](https://www.genophore.com) - Products - [Molecular Biology Suite](https://genophore.com/products/molecular_biology_suite/) - [Protein Sciences and Antibody Discovery](https://genophore.com/products/protein_sciences_and_antibody_discovery/) - [Structural Enablement](https://genophore.com/products/structural_enablement/) - [Connecting Biological and Chemical Knowledge](https://genophore.com/products/connecting_biological_and_chemical_knowledge/) - [Electronic Lab Notebook](https://genophore.com/products/electronic_lab_notebook/) - Technologies - [Data and Sequence Visualization](https://genophore.com/technologies/data_and_sequence_visualization/) - [Protein and DNA Parts Builder](https://genophore.com/technologies/protein_and_dna_parts_builder/) - [Workflows Builder](https://genophore.com/technologies/workflows_builder/) - [Customizable Data Structures](https://genophore.com/technologies/customizable_data_structures/) - Solutions - [Biopharmaceuticals & Biotech R&D](https://genophore.com/technologies/biotech_research_and_development/) - [Life Sciences](https://genophore.com/technologies/life_sciences/) - [Pricing](https://genophore.com/pricing/) - [Tools](https://info.genophore.com/tools) - [Blog](https://info.genophore.com/blog) - [Contact Us](https://genophore.com/contact/) - [Try Now](https://www.genophore.com/app) - [ML/AI](https://info.genophore.com/posts/tag/ml-ai) - [Drug Development](https://info.genophore.com/posts/tag/drug-development) - [Biologics](https://info.genophore.com/posts/tag/biologics) # AntiFold: Superior Structure-Based Antibody Sequence Design for Enhanced CDR Recovery May 19, 2024 ![Genophore](https://info.genophore.com/hubfs/Genophore_Profile_Logo_2024.png) [Genophore](https://info.genophore.com/posts/author/genophore)   The quest for designing effective and specific therapeutic antibodies (Abs) has been a cornerstone of modern biotechnology and pharmaceutical research. Antibodies, with their unique ability to bind to specific antigens, play a crucial role in the treatment of various diseases, including cancers, autoimmune disorders, and infectious diseases. However, the traditional methods of antibody development are often time-consuming and costly, requiring extensive experimental validation and optimization. In recent years, artificial intelligence (AI) and machine learning (ML) have emerged as powerful tools to streamline and enhance this process. By leveraging vast datasets and advanced algorithms, AI-driven models can predict antibody sequences and structures with remarkable accuracy, thus accelerating the development pipeline. One such breakthrough in this domain is the introduction of AntiFold, an antibody-specific model designed to harness the capabilities of the ESM-IF1 inverse folding framework for optimized antibody sequence design. This blog delves into the intricate workings of AntiFold and its potential to revolutionize therapeutic antibody development. Høie et al. recently introduced AntiFold, an antibody-specific model for structure-based sequence design based on the ESM-IF1 inverse folding model. ESM-IF1 is a general-purpose protein sequence design model for given protein structures, built by Meta by training on experimentally determined protein structures and over 12 million AlphaFold2-predicted structures. ![Post23_AntiFold_Fig](https://info.genophore.com/hs-fs/hubfs/Post23_AntiFold_Fig.png?width=475&height=566&name=Post23_AntiFold_Fig.png) Antibodies  are an important class of therapeutic agents with broad applications in treatments ranging from cancer to autoimmune disorders and viral infections. However, the development of therapeutic Abs is a challenging protein design problem as it involves not only sequence selection but also the optimization of multiple objectives, including efficacy, ease of manufacturing, safety, and more. Computational design is an ideal approach with huge potential to generate target-specific Abs. Although AI-based computational protein design has seen significant progress recently, with models like ProteinMPNN and ESM-IF1 achieving highly accurate sequence design for a wide range of proteins, the accurate design of Abs remains elusive. Several machine learning methods have demonstrated the ability to address some of the steps in the Ab development process, including reducing immunogenicity and aggregation. Other important tasks include the selection of sequence mutations that fit target structures and the optimization of structure-based properties such as stability and antigen binding. The AntiFold model was built by fine-tuning ESM-IF1 on datasets of experimental Ab structures (2,074 complexes from SAbDab) augmented with predicted Ab structures (147,458 ABodyBuilder2-modeled structures from OAS). Given a target Ab structure, the model predicts optimized sequences that would fold into the target structure. Sequences designed by AntiFold, when refolded using a structure prediction model, showed high structural similarity to the expected structure. In benchmarking tests against existing inverse folding models, including ProteinMPNN, ESM-IF1, and AbMPNN, AntiFold showed the highest sequence recovery of Ab complementarity-determining regions. When evaluated in a zero-shot antibody-antigen binding affinity test, AntiFold demonstrated better correlations than other methods. The accuracy of AntiFold was further improved when information about the target antigen was provided. AntiFold also shows promise in Ab optimization as it assigns low probabilities to residue mutations that ablate Ab-Ag binding. It remains to be seen how such a powerful model could be integrated into experimental settings for therapeutic Ab discovery as well as multi-objective optimization using reinforcement and active learning.   Paper: [AntiFold: Improved antibody structure-based design using inverse folding](https://doi.org/10.48550/arXiv.2405.03370) GitHub: [https://github.com/oxpig/AntiFold](https://github.com/oxpig/AntiFold) Webserver: [https://opig.stats.ox.ac.uk/webapps/antifold/](https://opig.stats.ox.ac.uk/webapps/antifold/) Colab Notebook: [https://colab.research.google.com/drive/1TTfgjoZx3mzF5u4e9b4Un9Y7b\_rqXc\_4](https://colab.research.google.com/drive/1TTfgjoZx3mzF5u4e9b4Un9Y7b_rqXc_4) Blog Post ## Related Articles [![](https://info.genophore.com/hubfs/Thumbnail%20Themes%20(28).svg)](https://info.genophore.com/posts/fabcon-can-antibody-specific-generative-foundation-model-facilitate-antibody-sequence-understanding) ### [FAbCon: Can antibody-specific generative foundation model facilitate antibody sequence understanding?](https://info.genophore.com/posts/fabcon-can-antibody-specific-generative-foundation-model-facilitate-antibody-sequence-understanding) May 27, 2024 [Protein Design](https://info.genophore.com/posts/tag/protein-design) [Generative Design](https://info.genophore.com/posts/tag/generative-design) [Drug Development](https://info.genophore.com/posts/tag/drug-development) [Biologics](https://info.genophore.com/posts/tag/biologics) [![Colorful and artistic image of a bispecific antibody with text indicating the content of the article.](https://info.genophore.com/hubfs/Thumbnail%20Themes%20(8).svg)](https://info.genophore.com/posts/igfold-how-deep-learning-on-0.5-billion-natural-antibody-sequence-and-graph-networks-can-facilitate-fast-antibodies-structure-prediction) ### [IgFold: How deep learning on 0.5 billion natural antibody sequences and graph networks can facilitate fast antibodies structure prediction](https://info.genophore.com/posts/igfold-how-deep-learning-on-0.5-billion-natural-antibody-sequence-and-graph-networks-can-facilitate-fast-antibodies-structure-prediction) June 23, 2024 [Protein Design](https://info.genophore.com/posts/tag/protein-design) [Structure Prediction](https://info.genophore.com/posts/tag/structure-prediction) [Generative Design](https://info.genophore.com/posts/tag/generative-design) [![](https://info.genophore.com/hubfs/ai-methods-in-antibody-presiction.svg)](https://info.genophore.com/posts/advanced-methods-in-antibody-structure-prediction-and-de-novo-generation) ### [AI Methods in Antibody Structure Prediction and De Novo Generation](https://info.genophore.com/posts/advanced-methods-in-antibody-structure-prediction-and-de-novo-generation) May 17, 2024 [Protein Design](https://info.genophore.com/posts/tag/protein-design) [Generative Design](https://info.genophore.com/posts/tag/generative-design) [Biologics](https://info.genophore.com/posts/tag/biologics) ##### Genophore - [Contact Us](https://genophore.com/contact/) - contact@genophore.com 8 The Green Dover DE 19901 United States [Follow us on LinkedIn](https://www.linkedin.com/company/genophore-inc/) [Follow us on Twitter](https://twitter.com/Genophore_Inc/) ##### Products - [Molecular Biology Suite](https://genophore.com/products/molecular_biology_suite/) - [Protein Sciences and Antibody Discovery](https://genophore.com/products/protein_sciences_and_antibody_discovery/) - [Structural Enablement](https://genophore.com/products/structural_enablement/) - [Connecting Biological and Chemical Knowledge](https://genophore.com/products/connecting_biological_and_chemical_knowledge/) - [Electronic Lab Notebook](https://genophore.com/products/electronic_lab_notebook/) ##### Technologies - [Data and Sequence Visualization](https://genophore.com/technologies/data_and_sequence_visualization/) - [Protein and DNA Parts Builder](https://genophore.com/technologies/protein_and_dna_parts_builder/) - [Workflows Builder](https://genophore.com/technologies/workflows_builder/) - [Customizable Data Structures](https://genophore.com/technologies/customizable_data_structures/) ##### Solutions - [Biopharmacuticals and Biotech R&D](https://genophore.com/technologies/biotech_research_and_development/) - [Life Sciences](https://genophore.com/technologies/life_sciences/) --- ©2024 Genophore - [Terms of Use](https://genophore.com/terms/) - [Privacy Policy](https://genophore.com/privacy/) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Genophore", "url" : "https://info.genophore.com/posts/author/genophore" }, "dateModified" : "2024-07-05T16:50:43.955Z", "datePublished" : "2024-05-19T20:47:06.000Z", "headline" : "AntiFold: Superior Structure-Based Antibody Sequence Design for Enhanced CDR Recovery", "image" : [ "https://info.genophore.com/hubfs/Thumbnail%20Themes%20(14).svg" ], "mainEntityOfPage" : { "@id" : "https://info.genophore.com/posts/antifold-superior-structure-based-antibody-sequence-design-for-enhanced-cdr-recovery", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject" } } } ```